DLA Piper advises Regor Pharmaceuticals in US$850 million sale of CDK inhibitors to Genentech

DLA Piper advised Regor Pharmaceuticals (USA), a part of clinical-stage biotechnology company Regor Therapeutics Group, in the sale of its breast cancer cyclin-dependent kinase (CDK) inhibitors portfolio to Genentech, a member of the Roche Group, for US$850 million.

Genentech will be responsible for clinical development, manufacturing and commercialization of the CDK inhibitors worldwide. Regor will continue to manage the two ongoing Phase 1 trials to their completion and will pursue and advance other distinct assets in oncology, metabolic diseases and auto-immunity.

The DLA Piper team was led by partners Adam Brenner and Jonathan Klein (both of New York) and included partners Alexandra Kamerling (London) and Paolo Morante (New York).

With more than 1,000 corporate lawyers globally, DLA Piper helps clients execute complex transactions seamlessly while supporting clients across all stages of development. The firm has been rated number one in global M&A volume for 15 consecutive years, according to Mergermarket, and ranked as a top five most active VC legal advisor in the US and number one in VC, PE and M&A in combined global deal volume according to PitchBook.